keyword
MENU ▼
Read by QxMD icon Read
search

Perindopril

keyword
https://www.readbyqxmd.com/read/28217527/vascular-legacy-hope-advances-to-empa-reg-and-leader-a-surprising-similarity
#1
Sanjay Kalra, Rakesh Sahay
Recently reported cardiovascular outcome studies on empagliflozin (EMPA-REG) and liraglutide (LEADER) have spurred interest in this field of diabetology. This commentary compares and contrasts these studies with two equally important outcome trials conducted using blood pressure lowering agents. A comparison with MICROHOPE (using ramipril) and ADVANCE (using perindopril + indapamide) blood pressure arms throws up interesting facts. The degree of blood pressure lowering, dissociation between cardiovascular and cerebrovascular benefits, and discordance between renal and retinal outcomes are surprisingly similar in these trials, conducted using disparate molecules...
January 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28204966/inhibition-of-the-renin-angiotensin-system-post-myocardial-infarction-prevents-inflammation-associated-acute-cardiac-rupture
#2
Xiao-Ming Gao, Alan Tsai, Annas Al-Sharea, Yidan Su, Shirley Moore, Li-Ping Han, Helen Kiriazis, Anthony M Dart, Andrew J Murphy, Xiao-Jun Du
PURPOSE: Inhibition of the renin-angiotensin system (RAS) is beneficial in patient management after myocardial infarction (MI). However, whether RAS inhibition also provides cardiac protection in the acute phase of MI is unclear. METHODS: Male 129sv mice underwent coronary artery occlusion to induce MI, followed by treatment with losartan (L, 20 and 60 mg/kg), perindopril (P, 2 and 6 mg/kg), amlodipine (20 mg/kg as a BP-lowering agent) or vehicle as control. Drug effects on hemodynamics were examined...
February 15, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/28181192/single-pill-combination-of-perindopril-indapamide-amlodipine-in-patients-with-uncontrolled-hypertension-a-randomized-controlled-trial
#3
Sergey V Nedogoda, Vesna J Stojanov
INTRODUCTION: Patients with hypertension often require a combination of three antihypertensive agents to achieve blood pressure control, but very few single-pill triple combinations are available. The aim of this study was to determine whether a single-pill triple combination of perindopril, indapamide, and amlodipine was as effective as a dual-pill combination of perindopril/indapamide plus separate amlodipine at reducing blood pressure in patients with uncontrolled, essential hypertension...
February 8, 2017: Cardiology and Therapy
https://www.readbyqxmd.com/read/28178210/perindopril-induces-tsp-1-expression-in-hypertensive-patients-with-endothelial-dysfunction-in-chronic-treatment
#4
Valentina Buda, Minodora Andor, Lucian Petrescu, Carmen Cristescu, Dana Emilia Baibata, Mirela Voicu, Melania Munteanu, Ioana Citu, Calin Muntean, Octavian Cretu, Mirela Cleopatra Tomescu
Thrombospondin-1 (TSP-1) is a potent endogenous inhibitor of both physiological and pathological angiogenesis, widely studied as a target in drug development for treating cancer. Several studies performed in the cardiovascular field on TSP-1 are contradictory, the role of TSP-1 in the physiopathology of cardiovascular disorders (CVDs) being, for the moment, incompletely understood and may be due to the presence of several domains in its structure which can stimulate many cellular receptors. It has been reported to inhibit NO-mediated signaling and to act on the angiogenesis, tissue perfusion, endothelial cell proliferation, and homeostasis, so we aimed to quantify the effect Perindopril has on TSP-1 plasma levels in hypertensive patients with endothelial dysfunction in comparison with other antihypertensive drugs, such as beta blockers, calcium channel blockers, and diuretics, in a chronic treatment...
February 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28169881/side-effects-and-tolerability-of-combination-blood-pressure-lowering-according-to-blood-pressure-levels-an-analysis-of-the-perindopril-protection-against-recurrent-stroke-study-and-action-in-diabetes-and-vascular-disease-preterax-and-diamicron-mr-controlled
#5
Emily R Atkins, Yoichiro Hirakawa, Abdul Salam, Mark Woodward, Mark Cooper, Pavel Hamet, Stephen Harrap, Kennedy Lees, Lisheng Liu, Giuseppe Mancia, Michel Marre, Vlado Perkovic, Neil Poulter, Bryan Williams, John Chalmers, Anthony Rodgers
OBJECTIVE: To measure the placebo-controlled effects of combination therapy on hypotension, treatment discontinuation, and major renal outcomes, according to baseline blood pressure. METHODS: We conducted an analysis of the action in diabetes and vascular disease: preterax and diamicron-MR controlled evaluation and perindopril protection against recurrent stroke study trials, including 14 684 participants allocated combination therapy or placebo. The mean age was 65 years, 61% were men, and 64% were receiving background blood pressure lowering (BPL) therapy...
February 6, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28168948/a-validated-hplc-method-for-simultaneous-determination-of-perindopril-arginine-amlodipine-and-indapamide-application-in-bulk-and-in-different-pharmaceutical-dosage-forms
#6
Ramzia I El-Bagary, Ehab F Elkady, Shereen Mowaka, Maria A Attallah
A simple, accurate, and precise LC method with a reversed stationary phase was developed and validated for the determination of perindopril (PER) arginine, amlodipine (AML), and indapamide (IND) alone and in binary mixtures (PER arginine is found in two dosage forms, i.e., with either AML or IND). Chromatographic separation was carried out on a BDS Hypersil<sup>®</sup> C18 column (100 × 3 mm, 5 μm). The mobile phase, consisting of 0.05 M potassium dihydrogen phosphate buffer (pH 2.6)-methanol(50 + 50, v/v), was pumped through the column whose temperature was maintained at 50°C at a flow rate of 0...
February 7, 2017: Journal of AOAC International
https://www.readbyqxmd.com/read/28150140/impact-of-statin-therapy-on-the-blood-pressure-lowering-efficacy-of-a-single-pill-perindopril-amlodipine-combination-in-hypertensive-patients-with-hypercholesterolemia
#7
Yuriy Sirenko, Ganna Radchenko
INTRODUCTION: Several lines of research indicate that statins can lower blood pressure (BP) independently of their lipid-lowering effects when used as monotherapy and in combination with antihypertensive agents. AIM: This short-term, open-label study examined whether statin therapy had a synergistic effect on the BP-lowering efficacy of perindopril/amlodipine in a subgroup of patients in the PERSPECTIVA study with concomitant hypertension and hypercholesterolemia, with or without statin at baseline...
February 2, 2017: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://www.readbyqxmd.com/read/28098840/comparative-solid-state-stability-of-perindopril-active-substance-vs-pharmaceutical-formulation
#8
Valentina Buda, Minodora Andor, Adriana Ledeti, Ionut Ledeti, Gabriela Vlase, Titus Vlase, Carmen Cristescu, Mirela Voicu, Liana Suciu, Mirela Cleopatra Tomescu
This paper presents the results obtained after studying the thermal stability and decomposition kinetics of perindopril erbumine as a pure active pharmaceutical ingredient as well as a solid pharmaceutical formulation containing the same active pharmaceutical ingredient (API). Since no data were found in the literature regarding the spectroscopic description, thermal behavior, or decomposition kinetics of perindopril, our goal was the evaluation of the compatibility of this antihypertensive agent with the excipients in the tablet under ambient conditions and to study the effect of thermal treatment on the stability of perindopril erbumine...
January 15, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28005036/-evaluation-of-the-pharmacoeconomic-efficacy-of-prestance-in-the-treatment-of-hypertensive-patients-on-the-basis-of-the-results-of-the-potential-program
#9
I N D'yakov, M G Glezer
AIM: To pharmacoeconomically estimate the use of a fixed-dose combination of perindopril and amlodipine in the treatment of hypertensive patients. MATERIAL AND METHODS: A pharmacoeconomic study was conducted on the basis of the Russian postmarketing observational open program POTENTIAL, which included the estimation of direct and indirect costs associated with the addition of a fixed-dose combination of perindopril and amlodipine to conventional therapy for hypertension in patients who had not achieved adequate blood pressure (BP) control...
2016: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28002478/the-effects-of-rilmenidine-and-perindopril-on-arousal-blood-pressure-during-24-hour-recordings-in-shr
#10
Kyungjoon Lim, Kristy L Jackson, Sandra L Burke, Geoffrey A Head
The surge in arterial pressure during arousal in the waking period is thought to be largely due to activation of the sympathetic nervous system. In this study we compared in SHR the effects of chronic administration of the centrally acting sympatholytic agent rilmenidine with an angiotensin converting enzyme inhibitor perindopril on the rate of rise and power of the surge in mean arterial pressure (MAP) that occurs with arousal associated with the onset of night. Recordings were made using radiotelemetry in 17 adult SHR before and after treatment with rilmenidine (2mg/kg/day), perindopril (1mg/kg/day) or vehicle in the drinking water for 2 weeks...
2016: PloS One
https://www.readbyqxmd.com/read/27974526/chronotherapy-for-hypertension-in-obstructive-sleep-apnoea-chosa-a-randomised-double-blind-placebo-controlled-crossover-trial
#11
Yasmina Serinel, Brendon J Yee, Ronald R Grunstein, Keith H Wong, Peter A Cistulli, Hisatomi Arima, Craig L Phillips
BACKGROUND: Obstructive sleep apnoea (OSA) is an important cause of secondary hypertension. Nocturnal hypertension is particularly prevalent in OSA and is a strong predictor of cardiovascular mortality. Studies in patients with essential hypertension have suggested that nocturnal administration of antihypertensives improves nocturnal blood pressure (BP) without elevating daytime BP. We evaluated the efficacy of this technique in patients with OSA with stage I/II hypertension, both before and after the addition of CPAP...
December 14, 2016: Thorax
https://www.readbyqxmd.com/read/27959372/construction-of-a-polyproline-structure-with-hydrophobic-exterior-using-octahydroindole-2-carboxylic-acid
#12
Vladimir Kubyshkin, Nediljko Budisa
The proline analogue (2S,3aS,7aS)-octahydroindole-2-carboxylic acid (Oic) has been previously applied as a proline substitute in pharmocologically active peptides and as a structural component of the antihypertensive drug Perindopril. Herein, we describe the formation of an oligoproline structure by an Oic oligomer. A series of Oic oligomers were investigated to show the structural and energetic contribution of appended residues to the structure. NMR investigation of these oligomers revealed an all-trans amide bond structure, and we provide evidence that a cascade-like mechanism is responsible for the all-trans folding cooperativity...
January 18, 2017: Organic & Biomolecular Chemistry
https://www.readbyqxmd.com/read/27893331/multidisciplinary-approach-to-novel-therapies-in-cardio-oncology-research-manticore-101-breast-a-randomized-trial-for-the-prevention-of-trastuzumab-associated-cardiotoxicity
#13
Edith Pituskin, John R Mackey, Sheri Koshman, Davinder Jassal, Marshall Pitz, Mark J Haykowsky, Joseph J Pagano, Kelvin Chow, Richard B Thompson, Larissa J Vos, Sunita Ghosh, Gavin Y Oudit, Justin A Ezekowitz, D Ian Paterson
Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive) breast cancer is dose-independent cardiac dysfunction. Angiotensin-converting enzyme inhibitors and β-blockers are recommended first-line agents for heart failure. We hypothesized that angiotensin-converting enzyme inhibitors and β-blockers could prevent trastuzumab-related cardiotoxicity. Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant therapy...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27878562/full-dose-perindopril-indapamide-in-the-treatment-of-difficult-to-control-hypertension-the-fortissimo-study
#14
Yuri Aleksandrovich Karpov
BACKGROUND AND OBJECTIVE: Blood pressure (BP) control in hypertensive patients remains poor worldwide, particularly in high-risk patients with hypertension and diabetes. Guidelines recommend that such patients receive prompt pharmacological therapy at maximal doses to rapidly control BP. We aimed to evaluate efficacy and safety of single-pill combination (SPC) perindopril/indapamide (PER/IND) at full dose (10/2.5 mg) in hypertensive patients, including diabetics, with BP uncontrolled by previous medication...
February 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27787528/the-active-modulation-of-drug-release-by-an-ionic-field-effect-transistor-for-an-ultra-low-power-implantable-nanofluidic-system
#15
Giacomo Bruno, Giancarlo Canavese, Xuewu Liu, Carly S Filgueira, Adriano Sacco, Danilo Demarchi, Mauro Ferrari, Alessandro Grattoni
We report an electro-nanofluidic membrane for tunable, ultra-low power drug delivery employing an ionic field effect transistor. Therapeutic release from a drug reservoir was successfully modulated, with high energy efficiency, by actively adjusting the surface charge of slit-nanochannels 50, 110, and 160 nm in size, by the polarization of a buried gate electrode and the consequent variation of the electrical double layer in the nanochannel. We demonstrated control over the transport of ionic species, including two relevant hypertension drugs, atenolol and perindopril, that could benefit from such modulation...
November 10, 2016: Nanoscale
https://www.readbyqxmd.com/read/27777044/renin-angiotensin-aldosterone-system-inhibitors-in-hypertension-is-there-evidence-for-benefit-independent-of-blood-pressure-reduction
#16
REVIEW
Chirag Bavishi, Sripal Bangalore, Franz H Messerli
The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the pathogenesis of hypertension (HTN). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are first line anti-HTN drug classes that are potent, effective and largely safe. Direct renin inhibitors (DRIs) have shown similar blood pressure (BP) reduction but more side effects. The efficacy of ACEIs and ARBs (for cardiovascular, cerebrovascular and renal protection) has been promoted to extend beyond what could be explained by BP reduction alone...
November 2016: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/27754299/lbos-01-06-integrated-approach-improved-blood-pressure-control-in-non-adherent-motivated-hypertensive-patients-prisma-study
#17
Svetlana Villevalde, Zhanna Kobalava
OBJECTIVE: Antihypertensive medication nonadherence is significant contributor to poor BP control. Patient-related factors (lack of motivation or risk understanding) are important. The aim of PRISMA study was to determine the impact of integrated approach with therapy based on perindopril arginine in the improvement of motivation, adherence to antihypertensive treatment and BP control. DESIGN AND METHOD: 906 (315 male, 56.0 ± 10.6 years) non-adherent (score < 4 in Morisky and Green Test for Measure of Adherence to Therapy) hypertensive patients with planning or action stages of behavior changes (Prochaska and DiClemente model) with uncontrolled hypertension (BP > 140/90 mmHg) were randomly assigned to 2 strategies: integrated approach with therapy based on perindopril arginine with added-on therapy if necessary (G1, n = 755) or routine practice (G2, n = 151)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27754028/yia-03-04-epigenetic-changes-after-acute-treatment-with-acute-angiotensin-converting-enzyme-inhibitors-acei
#18
Nathan De Vries, Priscilla Prestes, Indrajeet Rana, Stephen B Harrap, Fadi J Charchar
OBJECTIVE: The 'legacy effect' of hypertension treatment is where short term treatment with blood pressure (BP) lowering drugs such as angiotensin converting enzyme inhibitors (ACEi) is followed by a persistent reduction in BP, reduced cardiovascular complications and increased lifespan. However, the involvement of epigenetics mechanisms remains unclear. DNA methylation is the binding of a methyl group to DNA which inhibits gene transcription. The aim of this study is to investigate DNA methylation changes after short term treatment with ACEi...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27753981/pl-02-3-management-of-elderly-hypertension-whom-to-treat-and-how-low-to-go
#19
Michael Weber
: Age is the most powerful cardiovascular risk factor. Based on a meta-analysis of a million control patients in hypertension trials, the Clinical Trialists Collaboration has estimated that doubling of major cardiac and stroke events occurs with age increments of < 10 years (1). Data from the ACCOMPLISH trial, which will be presented at this ISH meeting for the first time, show that patients aged > 70 (mean: 75.2), compared with those < 70 (mean: 63.7), had a 2.82-fold greater event rate for cardiovascular death and a 2...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27643297/lbos-01-06-integrated-approach-improved-blood-pressure-control-in-non-adherent-motivated-hypertensive-patients-prisma-study
#20
Svetlana Villevalde, Zhanna Kobalava
OBJECTIVE: Antihypertensive medication nonadherence is significant contributor to poor BP control. Patient-related factors (lack of motivation or risk understanding) are important. The aim of PRISMA study was to determine the impact of integrated approach with therapy based on perindopril arginine in the improvement of motivation, adherence to antihypertensive treatment and BP control. DESIGN AND METHOD: 906 (315 male, 56.0 ± 10.6 years) non-adherent (score < 4 in Morisky and Green Test for Measure of Adherence to Therapy) hypertensive patients with planning or action stages of behavior changes (Prochaska and DiClemente model) with uncontrolled hypertension (BP > 140/90 mmHg) were randomly assigned to 2 strategies: integrated approach with therapy based on perindopril arginine with added-on therapy if necessary (G1, n = 755) or routine practice (G2, n = 151)...
September 2016: Journal of Hypertension
keyword
keyword
16394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"